对于双剂组合疗法的无模型I期剂量升级设计的比较
Helen Barnett1, Matthew George1,2, Donia Skanji3
1Department of Mathematics and Statistics, Lancaster University, Lancaster, UK.
Statistical methods in medical research
|January 24, 2024
概括
对于I期瘤学试验的无模型设计与基于模型的设计具有竞争力. 一项新的校准程序表明,无模型设计可以为选择最大耐受剂量组合提供更安全的替代方案.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 生物统计学 生物统计学
背景情况:
- 组合疗法在瘤学中很常见,提供潜在的益处,但增加了毒性风险.
- 一期试验的目的是确定最大耐受剂量 (MTD) 组合.
- 无模型设计正在成为传统基于规则或基于模型的设计的切实可行的替代方案.
研究的目的:
- 引入和评估一阶段瘤学试验中无模型设计的新型校准程序.
- 用模拟研究来比较无模型设计与基于模型的设计的性能.
- 评估无模型设计在识别MTD组合中的安全性和有效性.
主要方法:
- 开发一个校准程序,以优化无模型设计的参数.
- 综合模拟研究,比较各种临床场景的无模型和基于模型的设计.
- 将校准的无模型设计应用于现实世界I期瘤学试验数据集.
主要成果:
- 在选择正确的MTD组合时,无模型设计表现出与基于模型的设计具有竞争力的性能.
- 新的校准程序增强了无模型设计的理想参数.
- 在特定的临床场景中,无模型设计为剂量升级提供了更安全的方法.
结论:
- 无模型设计,特别是当校准时,是第一阶段瘤学试验的可行和有竞争力的选择.
- 拟议的校准方法提高了无模型设计的实际应用和安全性.
- 这些发现支持在瘤药物开发中更广泛地采用无模型设计来识别MTD.
相关概念视频
Drug Administration and Therapy Phases: Overview
468
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
468
Crossover Experiments
2.8K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
2.8K
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
62
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
62
Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K


